GlaxoSmithKline (GSK)

The two companies will test their vaccine's efficacy against variants and when used as a second dose following a first injection with another vaccine.

The companies said in a statement that "insufficient response in older adults demonstrates the need to refine concentration of antigen in order to provide high-level response across all age groups."